Zydus Lifesciences Limited CC-Dec24.pdf · 2025-02-05
Yeah. Hello, am I audible?
Thank you, Sir. Thanks for the opportunity. Couple of questions. First question is that about the US business. Obviously, we have seen a sequential decline. So, how much of that is because of the kind of competition in Asacol HD and how much is that because of, let's say, the base business weakness? That is one part and the second part of the US question is that Mirabegron supply, the export momentum from India, if you see , that looks really robust , while the execution, it seems not at par with the kind of export that we are making or the kind of inventory build -up that we have done. So, how should we think and how longer this Mirabegron opportunity can be considered for us?